TY - JOUR
T1 - Correction to
T2 - Superior silybin bioavailability of silybin–phosphatidylcholine complex in oily-medium soft-gel capsules versus conventional silymarin tablets in healthy volunteers* (BMC Pharmacology and Toxicology, (2019), 20, 1, (5), 10.1186/s40360-018-0280-8)
AU - Méndez-Sánchez, Nahum
AU - Dibildox-Martinez, Miguel
AU - Sosa-Noguera, Jahir
AU - Sánchez-Medal, Ramón
AU - Flores-Murrieta, Francisco J.
N1 - Publisher Copyright:
© The Author(s). 2021
PY - 2021/12
Y1 - 2021/12
N2 - After publication of the original article [1], an error was identified in the Results section, with regard to values of Table 1. The incorrect sentence is: SIB peak plasma concentrations were 207.1 mg/L for SPC and 12.6 mg/L for SM tablets. All pharmacokinetic parameters differed significantly between formulations (P < 0.0001). The correct sentence is: SIB peak plasma concentrations were 207.1 ng/L for SPC and 12.6 ng/L for SM tablets. All pharmacokinetic parameters differed significantly between formulations (P < 0.0001). The original article has been corrected.
AB - After publication of the original article [1], an error was identified in the Results section, with regard to values of Table 1. The incorrect sentence is: SIB peak plasma concentrations were 207.1 mg/L for SPC and 12.6 mg/L for SM tablets. All pharmacokinetic parameters differed significantly between formulations (P < 0.0001). The correct sentence is: SIB peak plasma concentrations were 207.1 ng/L for SPC and 12.6 ng/L for SM tablets. All pharmacokinetic parameters differed significantly between formulations (P < 0.0001). The original article has been corrected.
UR - http://www.scopus.com/inward/record.url?scp=85108895912&partnerID=8YFLogxK
U2 - 10.1186/s40360-021-00500-2
DO - 10.1186/s40360-021-00500-2
M3 - Comentario/Debate
C2 - 34172076
AN - SCOPUS:85108895912
SN - 2050-6511
VL - 22
JO - BMC Pharmacology and Toxicology
JF - BMC Pharmacology and Toxicology
IS - 1
M1 - 37
ER -